Financial Performance - Revenue for Q3 2022 was CNY 119,423,568.98, a decrease of 16.14% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 12,829,751.80, down 23.97% year-on-year[5] - Basic earnings per share for Q3 2022 was CNY 0.1604, a decline of 42.98% compared to the previous year[5] - Total operating revenue for Q3 2022 was CNY 316,598,072.90, a decrease of 18.8% compared to CNY 389,974,313.07 in the same period last year[19] - Net profit for Q3 2022 was CNY 36,591,811.86, representing a decline of 32.5% from CNY 54,206,098.58 in Q3 2021[19] - Earnings per share for Q3 2022 were CNY 0.5489, compared to CNY 0.9034 in the previous year, reflecting a decrease of 39.2%[20] Assets and Equity - Total assets at the end of Q3 2022 reached CNY 841,726,644.37, an increase of 58.91% from the end of the previous year[5] - Shareholders' equity attributable to the parent company was CNY 765,759,541.60, up 136.24% year-on-year[5] - The company's total liabilities decreased to CNY 75,967,102.77 from CNY 205,543,585.50, a reduction of 63.1% year-over-year[19] - The total equity attributable to shareholders increased to CNY 765,759,541.60 from CNY 324,148,372.84, an increase of 136.3%[19] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 26,354,840.08, down 14.05% compared to the previous year[5] - The net cash flow from operating activities for the current period is CNY 26,354,840.08, a decrease of 13.5% compared to CNY 30,663,156.56 in the previous period[22] - Total cash inflow from investment activities is CNY 301,666,987.42, significantly higher than CNY 58,055,379.20 in the previous period[22] - Cash inflow from financing activities amounts to CNY 446,938,473.00, compared to CNY 81,604,661.41 in the previous period, indicating a substantial increase[22] - The net cash flow from financing activities is CNY 292,691,432.97, up from CNY 76,885,519.80 in the previous period[22] Investment and Expenses - The company reported a significant increase in cash and cash equivalents, rising by 186.81% to CNY 346,770,699.58[9] - The company’s capital reserve increased by 903.69% to CNY 427,624,413.30 due to the initial public offering[9] - Research and development expenses for Q3 2022 were CNY 13,557,753.52, down 25.5% from CNY 18,135,558.29 in the same quarter last year[19] - The company experienced a 71.56% decrease in other income, totaling CNY 1,461,099.00, primarily due to changes in government subsidies[10] Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue growth[19]
美农生物(301156) - 2022 Q3 - 季度财报